EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigation of the Prevalence of Associated Genetic Mutations (Co-Mutations) in Patients with Actionable Driver Mutations in Lung Cancer: A Retrospective Study

Abed Agbarya iD, Walid Shalata iD, Edmond Sabo, Leonard Saiegh iD, Yuval Shaham, Haitam Nasrallah, Kamel Mhameed, Salam Mazareb, Mohammad Sheikh-Ahmad, Dan Levy Faber iD

Diagnostics · 07.04.2026 · 16 (7) · 1106

DOI: 10.3390/diagnostics16071106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 07.04.2026. Verfasst von Abed Agbarya und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 1 Efron Street, Haifa 3109601, Israel. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Lung cancer remains the leading cause of cancer-related mortality globally. Approximately 45% of these tumors harbor oncogenic mutations that drive carcinogenesis and are amenable to targeted therapies. Other predictive biomarkers—e.g., PD-L1, TMB, and MSI—play a crucial role in patients’ management. This study aims to investigate the existence of mutation clusters (co-mutations) and evaluate the correlation of these clusters with various clinical and laboratory parameters.

Methods

A retrospective study was conducted utilizing pathological samples from lung cancer patients harboring mutations in EGFR, KRAS, ALK, BRAF, MET, HER2, ROS1, NTRK, and NRG1. Data were collected from the Institute of Pathology at Carmel Medical Center between the years 2022 and 2024. Patients were stratified using a Two-Step Cluster Analysis algorithm based on actionable mutations and co-mutations. Heatmaps and dendrograms were generated to assess the correlation between these genomic clusters, clinical metrics, and predictive biomarkers.

Results

The study cohort included 129 patients with actionable mutations. Five distinct clusters were identified: Clusters 1, 2, and 3 exhibited a high expression of STK11 and TP53 co-mutations alongside KRAS drivers (n = 38, n = 12, and n = 23, respectively). Clusters 4 and 5 demonstrated high expression of ALK alterations and tumor suppressor gene mutations (n = 31 and n = 25, respectively). Cluster comparisons demonstrated statistically significant differences between clusters regarding age, gender, PD-L1 expression, and tumor mutational burden. No significant associations were found regarding ethnicity or microsatellite instability status.

Conclusions

By constructing clusters based on the aggregate of genomic alterations in patients with actionable mutations, it is possible to predict associations with distinct demographic and clinical characteristics. Future research should apply this analytical approach to larger cohorts to further characterize these subgroups and investigate potential correlations with therapeutic efficacy.

Schlagwörter

Stichwörter der Autor:innen

actionable mutationsco-mutationsdriver mutationsgenetic mutationsgenomic clusterlung cancer

Autor:innen und Institutionen

  • The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 1 Efron Street, Haifa 3109601, Israel.
  • Department of Oncology, Bnai-Zion Medical Center, 47 Eliyahu Golomb Avenue, Haifa 3339419, Israel.
  • The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, 151 Yitzhack Rager Avenue, Beer Sheva 8457108, Israel.
  • Faculty of Health Sciences, Ben Gurion University of the Negev, 1 Ben Gurion Avenue, Beer Sheva 8410501, Israel.
  • Pathology Institute, Lady Davis Carmel Medical Center, 7 Michal Street, Haifa 3436212, Israel.
  • Institute of Endocrinology, Bnai-Zion Medical Center, 47 Eliyahu Golomb Avenue, Haifa 3339419, Israel.

ORCID-Profile: Abed Agbarya, Walid Shalata, Leonard Saiegh, Dan Levy Faber

Zitieren

APA

Agbarya, A., Shalata, W., Sabo, E., Saiegh, L., Shaham, Y., Nasrallah, H., Mhameed, K., Mazareb, S., Sheikh-Ahmad, M., & Faber, D. L. (2026). Investigation of the Prevalence of Associated Genetic Mutations (Co-Mutations) in Patients with Actionable Driver Mutations in Lung Cancer: A Retrospective Study. Diagnostics, 16(7), 1106. https://doi.org/10.3390/diagnostics16071106

Vancouver

Agbarya A, Shalata W, Sabo E, Saiegh L, Shaham Y, Nasrallah H, et al. Investigation of the Prevalence of Associated Genetic Mutations (Co-Mutations) in Patients with Actionable Driver Mutations in Lung Cancer: A Retrospective Study. Diagnostics. 2026;16(7):1106. doi:10.3390/diagnostics16071106

BibTeX
@article{Agbarya2026,
  author = {Agbarya, Abed and Shalata, Walid and Sabo, Edmond and Saiegh, Leonard and Shaham, Yuval and Nasrallah, Haitam and Mhameed, Kamel and Mazareb, Salam and Sheikh-Ahmad, Mohammad and Faber, Dan Levy},
  title = {Investigation of the Prevalence of Associated Genetic Mutations (Co-Mutations) in Patients with Actionable Driver Mutations in Lung Cancer: A Retrospective Study},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {7},
  pages = {1106},
  doi = {10.3390/diagnostics16071106}
}
Kostenlos starten →